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Background: The UK Collaborative HIV Cohort (UK CHIC) is an observational study that collates data on HIV-positive
adults accessing HIV clinical care at (currently) 13 large clinics in the UK but does not collect pregnancy specific
data. The National Study of HIV in Pregnancy and Childhood (NSHPC) collates data on HIV-positive women
receiving antenatal care from every maternity unit in the UK and Ireland. Both studies collate pseudonymised data
and neither dataset contains unique patient identifiers. A methodology was developed to find and match records
for women reported to both studies thereby obtaining clinical and treatment data on pregnant HIV-positive
women not available from either dataset alone.
Results: Women in UK CHIC receiving HIV-clinical care in 1996–2009, were found in the NSHPC dataset by initially
‘linking’ records with identical date-of-birth, linked records were then accepted as a genuine ‘match’, if they had
further matching fields including CD4 test date. In total, 2063 women were found in both datasets, representing
23.1% of HIV-positive women with a pregnancy in the UK (n = 8932). Clinical data was available in UK CHIC
following most pregnancies (92.0%, 2471/2685 pregnancies starting before 2009). There was bias towards matching
women with repeat pregnancies (35.9% (741/2063) of women found in both datasets had a repeat pregnancy
compared to 21.9% (1502/6869) of women in NSHPC only) and matching women HIV diagnosed before their first
reported pregnancy (54.8% (1131/2063) compared to 47.7% (3278/6869), respectively).
Conclusions: Through the use of demographic data and clinical dates, records from two independent studies were
successfully matched, providing data not available from either study alone.
Keywords: Data linkage, HIV, Pregnant women, Antiretroviral therapy, Cohort analysis, United KingdomBackground
Antiretroviral therapy (ART) used during pregnancy in
combination with appropriate management of delivery
and avoidance of breastfeeding is highly effective at re-
ducing the risk of mother-to-child-transmission (MTCT)
of HIV [1,2]. As a result of this, and an increased life
expectancy of those living with HIV [3,4], many HIV-
positive women choose to have children [5]. Some do* Correspondence: susan.huntington.09@ucl.ac.uk
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distribution, and reproduction in any mediumnot yet require ART for their own health and use com-
bination ART, or zidovudine monotherapy, for a period
during pregnancy to prevent MTCT, repeating short-
term ART use in further pregnancies if they still do not
need treatment for their own health [6]. Women on
ART at conception are recommended to continue treat-
ment throughout pregnancy and after [6]. The implica-
tions of exposure to short-term antenatal ART with
respect to women’s longer term health and future treat-
ment responses are incompletely understood [7–10].
Adult HIV cohorts have contributed to understanding
HIV disease progression and its management, but may
not collect data on childbearing or pregnancy status,ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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nancy and rarely collect data on maternal disease pro-
gression and treatment post-delivery. In the UK,
comprehensive national surveillance of HIV-positive
pregnant women is carried out by the National Study of
HIV in Pregnancy and Childhood (NSHPC), but data are
limited to information available throughout pregnancy
and shortly after [11,12]. The UK Collaborative HIV
Cohort (UK CHIC) study collates extensive data,
recorded as part of a patient’s clinical record, on adults
seen for HIV-related care at large HIV clinics in the UK
[13]. This provides information on patients’ long-term
follow-up, but pregnancy-specific data are not recorded.
In order to study the long-term impact of antenatal
ART use on the health of HIV-positive women, collabor-
ation between NSHPC and UK CHIC was established
and a methodology developed to find and match records
for women reported to both. This paper describes the
matching strategy and estimates the completeness of
matching and the extent to which HIV-positive pregnant
women in UK CHIC were representative of HIV-positive
pregnant women in the UK.
Methods
The NSHPC and UK CHIC datasets were compared to
find and match the records of women reported to both
i.e. women in UK CHIC who had been pregnant. Initial
attempts using only demographic variables (date-of-birth
(DOB), country-of-birth (COB), and ethnicity) led to in-
complete matching and created false matches; 1575
women were matched, 156 (9.9%) matching multiple
records. Therefore, deterministic decision criteria based
on both demographic and clinical fields were devised.
Data collection
The NSHPC surveillance programme collects data on
HIV-positive pregnant women from all maternity units
in the UK and Ireland (~240 units) under the auspices
of the Royal College of Obstetricians and Gynaecolo-
gists. A designated individual from each site, typically a
midwife or physician, completes standard reporting
forms each quarter which are collated at the Institute of
Child Health and transcribed into an electronic database.
Data collected include: DOB, probable route of infection,
ethnicity, COB, date of UK arrival (if born abroad), date
of UK HIV-diagnosis, expected and actual dates of deliv-
ery, ART use during pregnancy including start and stop
dates, pregnancy outcome and first and last CD4 count
and viral load assessments during pregnancy. Soundex, a
non-unique code derived from the patient’s surname,
has been requested since 2008 [14], and is not yet com-
prehensively provided (3.4%, (306/8932) records
included soundex). Further details about NSHPC are
available elsewhere [1,15].The UK CHIC study is an observational cohort of HIV-
positive adults (aged 16 and older) attending for clinical
care at (currently) 13 large UK clinics (see acknowledge-
ments). Each year electronic data are extracted from
patients’ clinical records and transferred securely to the
coordinating centre where duplicate records for the same
individual, seen at different sites, are merged [13]. Data
collected include: DOB, soundex, probable route of infec-
tion, ethnicity, COB, date of HIV-diagnosis in the UK, date
and result of all CD4 counts and viral load assessments,
use of ART including start and stop dates. Further details
are available elsewhere [13,16,17].
Initial matching was undertaken in 2009 [18] and
repeated in 2010 using updated datasets [19]. The
matching process was formalised in 2011, the results of
which are presented here. The UK CHIC dataset com-
prised 8286 women, aged 16–49, seen since 1st January
1996 to 31st December 2009. A restricted NSHPC data-
set comprised 8932 women with 11,771 pregnancies
starting after 1995 and reported by the end of 2010.
Dataset linkage using DOB
Initially, records in NSHPC with a DOB identical to a
record in UK CHIC were ‘linked’ and included in a tem-
porary dataset referred to as the ‘linked DOB dataset’.
Some women appeared multiple times in this dataset, as
they were linked to multiple records with the same
DOB. A series of criteria were then used (as described
below) to assess which pairs were a genuine match.
If records were confirmed as a ‘match’ (i.e. the NSHPC
record referred to the same woman as the UK CHIC
record) they were merged and moved to a ‘combined
dataset’. All remaining occurrences of these women (i.e.
as part of other linked pairs) were removed from the
linked DOB dataset. The next stage of matching was
then undertaken for pairs of records remaining in the
linked DOB dataset (Figure 1). If at any stage a record
was matched to multiple records, these were reviewed
to identify the strongest match.
Criteria used to find matching records
CD4 date
Initially CD4 date was used to assess whether linked
records were a genuine match (Figure 1). Firstly, records
with any exactly matching CD4 date and CD4 count
within 10 cells/mm3 on that date (to take account of
rounding up or down to the nearest 10 cells/mm3),
in their NSHPC and UK CHIC records, were considered
a match and moved to the combined dataset. Next, any
records with an exactly matching CD4 date but with a
CD4 count (on that date) that differed by >10 cells/mm3
were considered a genuine match if they had either iden-
tical HIV-diagnosis date or were seen for routine HIV
care and antenatal care at the same site. Where the
Figure 1 Criteria used to match records for women reported to NSHPC and UK CHIC. *Pairs were removed as one or both records in the
pair were confirmed as a match in a different pair.
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these were manually checked. Sites providing HIV ser-
vices located close to sites providing maternity care were
considered as the same site.
The same criteria were then used to confirm matches
among the remaining records in the linked DOB dataset
which had CD4 dates that did not match exactly but
which were <30 days apart (Figure 1).ART start and stop dates
ART drug start and stop dates were then used to identify
further matches from the linked DOB dataset (records
not confirmed as a match using CD4 data). Five criteria
were used in the following order: where drug and start
and stop dates all exactly matched; where drug matched
and either the start or stop date exactly matched; where
drug did not match or was missing but start and stop
dates exactly matched; where either start or stop date
exactly matched and records were reported from the
same site; and where either start or stop date exactly
matched and HIV diagnosis date matched. The process
was repeated for records without exactly matching ART
start and stop dates but where the respective dates were
≤7 days apart (Figure 1).Manual checking
Finally, records remaining in the linked DOB dataset
(records not confirmed as a match using CD4 or ART
data) were manually checked to find further matches,
using fields including: COB, ethnicity, HIV-diagnosis
date, viral load and date, ART start and stop dates and
site of care. Records were selected for manual checking
if they had been reported from the same site, had HIV-
diagnosis dates ≤30 days apart, any drug start or stop
date match, matching soundex or an ART profile, in UK
CHIC, which indicated they may have had a pregnancy.
This included women with an ART start date in UK
CHIC during the pregnancy (after the first trimester)
and who either started zidovudine monotherapy or com-
bination ART with CD4> 350 cells/mm3 or who had
“pregnant” reported as a reason for starting or stopping
ART (in UK CHIC).Discrepancy checking
At each stage, before records were merged and moved
to the combined dataset, matched records with a dis-
crepancy in COB or ethnicity, variables collected by both
studies, were manually checked. Records were also
checked if there was a date of death (in UK CHIC)
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reported as drug naïve in UK CHIC after antenatal ART
start dates in NSHPC or had a date of UK arrival (in
NSHPC) after a CD4 count or viral load assessment in
UK CHIC. Records with a discrepancy were kept as a
match (and assumed to be due to typographic error) if
they had sufficient data in agreement in other fields,
such as viral load and HIV-diagnosis date, to indicate
that they were a genuine match. Discrepancy checking
resulted in 43 matched pairs being un-matched.
Where there was a discrepancy in fields collected by
both studies, records were examined to identify which
data should be used, as described below.
HIV-diagnosis date
The earliest HIV-diagnosis date from either study was
used unless one date was either 1st January or 30th June
(proxy dates used when only year of diagnosis is known/
reported) and the later date was during the same year, in
which case the later date was used (n = 116). The earliest
CD4 count, viral load assessment or ART start date was
used if no HIV-diagnosis date was available (n = 4), or
preceded the earliest HIV-diagnosis date (n = 78).
Region of birth
Region of birth (ROB) was categorized using COB, as
defined by the World Health Organization [20]. Records
with discrepant ROB (n = 98) were categorized as the
non-European region if region was European in one
dataset and non-European in the other (n = 96) (94 of
which had UK as COB in one study), otherwise ROB
was categorized as ‘Not Known’ (n = 2).
Ethnicity
Where ethnicity was somewhat discrepant, for example
‘black-other’ versus ‘other’ (n = 161), UK CHIC data was
used in the final dataset (as ethnicity is reported multiple
times for women seen in multiple years in UK CHIC).
Where there was a strong discrepancy (n = 17), such as
‘black’ versus ‘white’, ethnicity was categorised as ‘not
known’ (n = 8). These records had been checked during
the matching process and had sufficient matching data
in other fields, including COB, to indicate that they were
a genuine match.
Data analysis
Matching and data analysis was carried out using SAS v
9.1 (SAS Institute Inc. Cary, NC, USA). HIV-positive
women with a pregnancy (reported to NSHPC) whose
record was found in UK CHIC (referred to as ’matched’)
were compared to HIV-positive women with a preg-
nancy who were not found in UK CHIC (referred to as
‘non-matched’), to indicate whether women in UK CHIC
with a pregnancy were representative of HIV-positivewomen with a pregnancy. Logistic regression was used
to compare characteristics and Mann–Whitney test was
used to compare median ages.
National HIV surveillance data from the Survey of
Prevalent HIV Infections Diagnosed (SOPHID) were
used to estimate the proportion of women seen for HIV-
related clinical care in the UK included in UK CHIC.
SOPHID was also used in combination with NSHPC
data to estimate the completeness of matching [21].
Results
Of the 8286 women reported to UK CHIC, 24.9%
(n = 2063) had a record in the NSHPC dataset, indicating
that they had ever had a pregnancy in the UK when
HIV-positive. The records for these women were merged
to create a ‘combined dataset’. The majority of matching
records were identified using exact CD4 date or CD4
date ±30 days (Table 1).
Characteristics of women in the combined dataset
Nearly three-quarters of women in the combined dataset
were black-African, most were born in Africa and the
majority were infected via heterosexual sex (Table 2).
Less than half were HIV-diagnosed during their first
reported pregnancy and 21 were diagnosed perinatally
(12 of these women had a subsequent pregnancy). The
majority of pregnancies resulted in a live birth (Table 2)
and the median number of pregnancies was 1 (range 1, 6).
There were 3035 pregnancies in total, the number
increasing from 159 in 2000 to 280 in 2009. Most women
(92.1%, n=1899) attended HIV-clinical care and antenatal
care at the same hospital.
Completeness of matching
The number of women (aged 16–49 years) in the UK
CHIC dataset increased yearly; from 2036 in 1996 to
4755 in 2009, totalling 45,768 person years and repre-
senting approximately 29.5% (37,577/127,267 person
years) of HIV-positive women (aged 16–49) attending
HIV care in the UK in 2000–2009 [21].
In 2009, there 19,312 women (aged 16–49) seen for
HIV-clinical care in the UK (according to national HIV-
surveillance data) [14] and 1198 HIV-positive women
with a pregnancy (1211 pregnancies) starting that year
(according to the NSHPC dataset used in this study),
indicating that approximately 6.2% (1198/19,312) of
women seen for HIV-care in 2009 became pregnant that
year. We would therefore anticipate that 279–311
women (95% confidence interval for 6.2% of 4755) in the
UK CHIC dataset had a pregnancy in 2009. The com-
bined dataset contained 275 women with a pregnancy in
2009, lower than the anticipated range.
Of the records linked using DOB which did not meet
the matching criteria (4916 pairs; 3014 UK CHIC
Table 1 Criteria used to find records for HIV-positive women reported to NSHPC and UK CHIC
Criteria used to find records (All pairs of records have the same DOB) Records matched (n= 2063)
N % Cumulative%
Exact CD4 date CD4± 10 cells/mm3 1492 72.3 72.3
HIV diagnosis date/site 39 1.9 74.2
CD4 date ±30 days CD4± 10 cells/mm3 251 12.2 86.4
HIV diagnosis date/site 59 2.9 89.2
ART drug start and stop dates Exact dates 64 3.1 92.3
Dates ±7 days 48 2.3 94.7
Manual Site match 58 2.8 97.5
Diagnosis date ±30 days 4 0.2 97.7
Drug start or stop dates 2 0.1 97.8
Soundex 7 0.3 98.1
ART profile 39 1.9 100.0
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to multiple records with the same DOB), 137 (2.8%) pairs
had ever been seen at the same site for antenatal and rou-
tine HIV care and had clinical data in UK CHIC at the
time they were pregnant. Over half of these (53.3%, 73/
137) had CD4 data reported to NSHPC, but only 4 were
within 30 days of a CD4 date in UK CHIC and these had
discrepant CD4 counts and HIV-diagnosis dates.
Availability of pre and post-pregnancy clinical data
Half (49.6%, n = 1024) the women in the combined data-
set had data in UK CHIC prior to their first reported
pregnancy; these women had clinical data in UK CHIC
for a median of 2.8 (IQR 1.2-5.4) years before the preg-
nancy. The majority of pregnancies (starting before
2009) had CD4 or viral load data in UK CHIC following
the pregnancy (92.0%, 2471/2685), for a median of 3.8
(IQR 1.8-6.4) years and the median time between deliv-
ery and next viral load or CD4 assessment was 1.8 (IQR
1.1-3.5) months. The majority of pregnancies with no
postnatal data in UK CHIC, resulted in a live-birth
(92.5%, 198/214) and less than half (36.0%, 77/214) had
data in UK CHIC before the pregnancy. As no data on
departure from the UK was available it was not possible
to determine whether women with no post-delivery data
had left the UK. However, women with no postnatal data
did not significantly differ from women with postnatal
data in the proportion with a UK date of arrival (61.0%
(1523/2496) compared to 60.8% (115/189), Chi-squared
test p = 0.96) or the median time between UK arrival and
giving birth (4.1 (IQR 2.0-7.3) compared to 3.0 (IQR 1.0-
5.8) years, Mann–Whitney test p< 0.20).
Representativeness of pregnant women in UK CHIC
Women found in both NSHPC and UK CHIC, referred
to as ‘matched’ (n = 2063) differed in some ways from
women in NSHPC only, referred to as ‘non-matched’(n = 6869). A smaller proportion of matched than non-
matched women had a first pregnancy where the out-
come had not yet been reported (i.e. outcome was
reported as ‘continuing to term’); 1.5% (n = 30) com-
pared to 5.0% (n = 342) respectively, OR 0.28 [0.19-0.41],
p< 0.001); the majority of pregnancies continuing to
term started in 2009/10 (73%, 273/372). When first
pregnancies with an ‘other/missing’ outcome (i.e. women
who left the UK or who were lost to follow-up, 6 non-
matched records and 0 matched) and pregnancies where
outcome was not yet reported were excluded, the out-
comes for first pregnancies were similar for matched
and non-matched women (Chi-squared test p = 0.15),
with 90.2% (1834/2033) compared to 88.7% (5782/6521)
resulting in a live birth respectively.
Timing of HIV-diagnosis varied between matched and
non-matched women; with 54.8% (n = 1131) diagnosed
before their first reported pregnancy compared to 47.7%
(n = 3278) respectively, OR 1.34 [1.21-1.48], p< 0.001).
A somewhat higher proportion of matched than non-
matched women had repeat pregnancies; 35.9% (n = 741)
compared to 21.9% (n = 1502) respectively, OR 2.00
[1.80-2.23], p< 0.001).
Matched women were more likely to attend antenatal
care in London than non-matched women (83.2%
(n = 1717) compared to 36.8% (n = 2530) respectively,
OR 8.5 [7.5-9.6], p< 0.001) and were slightly older at
the start of their first pregnancy (median age: matched
women 30.4 (IQR 26.5-34.3) years, non-matched women
29.6 (IQR 25.8-33.6) years, p< 0.001). Ethnicity varied
somewhat - a smaller proportion of matched women
were black-African compared to non-matched women
(74.4% (n = 1535) compared to 78.1% (n = 5362), OR 0.82
[0.73-0.92], p< 0.001); this difference remained signifi-
cant when ‘ever seen for antenatal care in London’ was
included in the model (AOR 0.67 [0.58-0.76], p< 0.001).
A higher proportion of matched women were black-
Table 2 Characteristics of women in the combined dataset (n = 2063)
n %





Region of birth* African 1527 74.0
European 347 16.8
Region of the Americas 87 4.2
Eastern Mediterranean 53 2.6
South-East Asia 25 1.2
Western Pacific 16 0.8
NK 8 0.4
Probable route of infection† Heterosexual sex 1798 87.2
Injecting drug use 40 1.9
Other 135 6.5
NK 90 4.4
Age at start of first pregnancy (years) Median (IQR) 30.4 (26.5-34.3)
Range 14-49
HIV-diagnosis in relation to first reported pregnancy Before pregnancy 1131 54.8
During first pregnancy 911 44.2
At delivery 21 1.0




Ectopic pregnancy 4 0.1
Continuing to term 75 2.5
* WHO World Regions [31].
† Using UK CHIC categories and data.
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compared to 3.4% (n = 230) respectively, OR 1.53 [1.21-
1.94], p< 0.001), but this difference was attenuated after
adjustment for antenatal care in London (AOR 1.00
[0.78-1.29], p = 0.99). The proportion of women who
were white was similar among matched and non-
matched women (11.8% (n = 243) and 13.4% (n = 919)
respectively, OR 0.86 [0.74-1.01], p = 0.06 and AOR 1.4
[1.18-1.65] p< 0.001 after adjustment for antenatal care
in London).
In the UK CHIC dataset, 84.6% (7014/8286) of women
had ever attended care in London, and of those attend-
ing care in 2009, 82.1% (3906/4755) went to a London
site. In the NSHPC dataset, 47.6%, (4247/8932) of
women had ever had antenatal care in London. Women
attending antenatal care in London differed somewhat
from women attending care elsewhere, for example, they
were older at the start of their first pregnancy (31.1and 29.6 years respectively, p< 0.001), more likely to be
black-African or black-Caribbean and less likely to be
white than women attending care outside London
(black-African: 79.8% (3390/4247) compared to 74.9%
(3507/4685), OR 1.3 [1.2-1.5], p< 0.001; black-Caribbean:
5.7% (n= 240) compared to 2.0% (n= 94), OR 2.9 [2.3-3.7],
p< 0.001; and white: 8.1% (n= 346) compared to 17.4%
(n= 816), OR 0.42 [0.37-0.48], p< 0.001 respectively). The
proportion of women diagnosed before their first preg-
nancy was similar for women seen in London and seen
elsewhere, (48.5% (2061/4247) and 50.5% (2366/4685) re-
spectively, Chi-squared test, p = 0.06).
Discussion
Using deterministic decision criteria based on demo-
graphic data and clinical dates collected by NSHPC and
UK CHIC we were able to determine that as a minimum
estimate almost one-quarter of women who received
Huntington et al. BMC Medical Research Methodology 2012, 12:110 Page 7 of 9
http://www.biomedcentral.com/1471-2288/12/110HIV-clinical care at UK CHIC sites in 1996–2009 had a
pregnancy. This method combined the use of automated
matching with manual review of selected records, as has
been used elsewhere [22–26] and can be repeated in
future years.
As no ‘gold-standard’ was available to calculate the
completeness of the matching, national HIV surveillance
data of individuals attending HIV-related care, was used
to estimate the expected number of women with a preg-
nancy in the UK CHIC dataset. The number of women
with a pregnancy in our combined dataset was less than
the anticipated range in 2009, indicating that there was a
high but incomplete level of matching. This estimation
assumes that all women in the NSHPC are reported to
SOPHID, which previous linkage studies indicate is not
the case [27], so the true level of matching may be
higher than this estimate. A large number of records had
identical DOB but were not matched as they did not
meet the matching criteria. It is unlikely that many of
these were genuine matches as we would expect some
women to share birth dates given the number of women
in both datasets, particularly as women who do not
know their DOB sometimes use common proxy dates,
for example where the date matches the month (1st
January, 2nd February, etc.) [28]. Records with identical
dates of birth which matched on site but no other vari-
ables (137 pairs) may have been genuine matches; how-
ever, for this dataset under-matching is preferable to
creating false matches. We anticipate that with the in-
clusion of additional data for women with repeat preg-
nancies and developments in software and data
collection at clinics there will be more complete match-
ing in future years.
There are a number of limitations to the methodology,
including the use of blocking to select records, in this
instance DOB. This is effective at limiting the records in
the matching process to those likely to be matches and
is frequently used in matching large datasets [24,29,30].
However, it means that incorrect or inconsistent report-
ing of DOB results in a record being excluded; which
may be more common among some groups than others,
potentially introducing bias [28,31]. Use of demographic
data for record matching, such as age, ethnicity,
and COB, within any matching algorithm are likely to
create some false matches. Given our study population,
multiple women had the same ethnicity, COB, and age,
so the additional use of clinical data was crucial for
matching. However, this resulted in some selection bias,
as women with more clinical data, either because they
had been diagnosed prior to pregnancy or had repeat
pregnancies, were more likely to be matched also indi-
cating that the matching was somewhat incomplete.
Other differences between matched and non-matched
women, such as age at first pregnancy, could beattributed to the difference in the proportion attending
care in London, as much of the UK CHIC data comes
from London sites. The differences in ethnicity between
matched and non-matched women may also be
explained by differences in ethnicity between women
attending care in and outside London. However, when
taking this into account, black-African women were less
likely to be matched than women of other ethnicities
and white women were more likely to be matched.
Data discrepancies in fields common to both studies
were harmonized where possible, or else categorized as
‘not known’. Discrepancies were unlikely to be a result
of incorrect matching, as matched records with strong
discrepancies were manually checked for additional
matching variables. A woman’s antenatal data, used for
completing the NSHPC reporting form, and HIV clinical
data extracted for inclusion in UK CHIC, are typically
stored separately, even within the same hospital, in order
to maintain patient confidentiality. Reasons why these
databases might be discrepant include incorrect or
incomplete recording of data and inconsistent or
inaccurate reporting by patients, for example where
language is a problem or DOB is unknown [28].
This matching approach could be replicated in other
settings, specifically large datasets which contain some
or all of the same individuals and which include com-
mon clinical and demographic variables but no unique
identifiers, for example, investigating the transition from
adolescent to adult HIV-care by matching these separate
datasets. Combining two datasets can lead to problems,
as experienced here, such as discrepancies in variables
available in both datasets and may introduce bias in
matching records containing more clinical data. Never-
theless, the combining of datasets can provide the
opportunity to study data not available from either study
alone. Combining NSHPC with UK CHIC allows the
study of predictors of pregnancy and changes in preg-
nancy incidence over time among women accessing
HIV-care [32] and provides the opportunity to investi-
gate the long-term impact of antenatal ART use on the
woman’s health and future treatment responses.
Conclusions
This matching process, used to identify HIV-positive
women reported to NSHPC and UK CHIC, shows that
with well considered use of demographic data and clin-
ical dates, combined with careful manual review, it is
possible to merge data from independent studies, provid-
ing useful data not available from either dataset alone.
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